BACKGROUND: Inhibitor antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII. METHODS: From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children's Hospital were evaluated. Those who had abnormal mixing study, antibody against FVIII were measured. Data were collected and analyzed. RESULTS: The age range of the patients was 4-60 years. The inhibitor antibody was seen in 9 (17.3%) patients. The mean age of patients with inhibitor at the time of diagnosis was 10.22 years (ranged 4-31 years). Old patients had more hemarthrosis than young patients. The mean level of inhibitor antibody was 8.47 Bethesda unit (ranged 2.3-29). Six patients had inhibitor antibody level ≥5 Bethesda unit and three patients had inhibitor antibody level <5 Bethesda unit. CONCLUSION: This study showed that the prevalence of inhibitor antibodies in young patients is more than the old patients.
BACKGROUND: Inhibitor antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII. METHODS: From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children's Hospital were evaluated. Those who had abnormal mixing study, antibody against FVIII were measured. Data were collected and analyzed. RESULTS: The age range of the patients was 4-60 years. The inhibitor antibody was seen in 9 (17.3%) patients. The mean age of patients with inhibitor at the time of diagnosis was 10.22 years (ranged 4-31 years). Old patients had more hemarthrosis than young patients. The mean level of inhibitor antibody was 8.47 Bethesda unit (ranged 2.3-29). Six patients had inhibitor antibody level ≥5 Bethesda unit and three patients had inhibitor antibody level <5 Bethesda unit. CONCLUSION: This study showed that the prevalence of inhibitor antibodies in young patients is more than the old patients.
Entities:
Keywords:
Hemarthrosis; Inhibitory antibody; concentrated FVIII; hemophilia A
Authors: T Takase; F Rotblat; A H Goodall; P B Kernoff; S Middleton; S Chand; K W Denson; D E Austen; E G Tuddenham Journal: Br J Haematol Date: 1987-08 Impact factor: 6.998
Authors: A Shirahata; K Fukutake; S Higasa; J Mimaya; T Oka; M Shima; J Takamatsu; M Taki; M Taneichi; A Yoshioka Journal: Haemophilia Date: 2011-06-20 Impact factor: 4.287
Authors: A Zakarija; S Harris; A W Rademaker; J Brewer; J Krudysz-Amblo; S Butenas; K G Mann; D Green Journal: Haemophilia Date: 2011-02-07 Impact factor: 4.287
Authors: Pilar Casaña; Noelia Cabrera; Ana Rosa Cid; Saturnino Haya; Magdalena Beneyto; Carmen Espinós; Vicente Cortina; Maria Angeles Dasí; Josè Antonio Aznar Journal: Haematologica Date: 2008-04-09 Impact factor: 9.941